ライフサイエンスコーパス: IU

1 ificantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL,

2 ersus 8.4 IU/L; interquartile range, 7.6-9.0 IU/L; P<0.01), these patients were moderately anemic (me

3 d by probit analysis was between 6.2 and 9.0 IU/ml.

4 with interferon-gamma values less than 4.00 IU/mL (47 [77%] of 61).

5 th interferon-gamma values between 0.35-4.00 IU/mL (IRR 11.4 [95% CI 2.4-107.2]; p=0.00047).

6 at interferon-gamma values between 0.35-4.00 IU/mL did not have significantly increased risk of disea

7 at interferon-gamma values higher than 4.00 IU/mL was associated with substantially increased diseas

8 amma <0.35 IU/mL, 0.35-4.00 IU/mL, and >4.00 IU/mL) at the intermediate study visit (day 336) and det

9 at very high interferon-gamma values (>4.00 IU/mL) warrants intensified diagnostic and preventive in

10 ult (interferon-gamma <0.35 IU/mL, 0.35-4.00 IU/mL, and >4.00 IU/mL) at the intermediate study visit

11 </=3.25) and with baseline HCV RNA<6,000,000 IU/mL, SVR rates were 93.2% (1,020/1,094) for those who

12 say quantification range of 100 to 5,000,000 IU/ml.

13 nd have a pretreatment viral load <6,000,000 IU/mL.

14 er, under CT guidance, human thrombin (1,000 IU) was injected inside the aneurysmatic sac with its co

15 peans), vitamin D supplement use of >/=1,000 IU/day (18.9 nmol/L (95% confidence interval (CI): 16.1,

16 ed with HCV genotypes 1-6 (HCV RNA >/=10 000 IU/mL) with or without compensated cirrhosis.

17 1, 2, or 3, with HCV RNA of at least 10 000 IU/mL, without evidence of cirrhosis, who had not receiv

18 rol (vitamin D3) followed by monthly 100 000 IU (2.5 mg) colecalciferol or equivalent placebo dosing.

19 e bolus vitamin D supplementation of 100 000 IU colecalciferol monthly over 2.5-4.2 years did not pre

20 receive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d

21 ceive four biweekly doses of 3.5 mg (140,000 IU) vitamin D3 (n = 190) or placebo (n = 200) during int

22 njection, followed by a fixed dose of 15 000 IU/m(2) bleomycin by intravenous infusion on day 4.

23 t elevated serum levels of HCV RNA (>167,000 IU/mL) and HCV genotype 1 are strong predictors of ESRD,

24 ith plasma HBV DNA concentrations of >20 000 IU/mL), serum alanine aminotransferase concentrations of

25 ir F2-4) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

26 213) and high-replicative (HBV DNA >/=20,000 IU/mL, n = 153) patients was assessed.

27 ceive either an initial oral dose of 200 000 IU (5.0 mg) colecalciferol (vitamin D3) followed by mont

28 Median baseline HCV RNA was 2 280 000 IU/mL (interquartile range, 272 000-4 230 000).

29 erved oral doses of cholecalciferol (300,000 IU) or matching placebo at baseline and 8 weeks.

30 areas under the curve were 22 000 and 38 000 IU.h in the NAC and placebo groups, respectively (P=0.08

31 1 year of vitamin D3 supplementation (4,000 IU [100 mug] daily) or matching non-calcium-based placeb

32 cancer, were randomly assigned to EPO 40,000 IU subcutaneously once a week or best standard of care.

33 Baseline HCV RNA < 400,000 IU/ml (OR = 1.96; 95% CI, 1.13-3.39; P = 0.02) was the o

34 us TILs and high-dose interleukin-2 [720 000 IU/kg] every 8 h).

35 ulative bleomycin doses (OR, 1.44 per 90,000 IU) were significantly associated with five or more AHOs

36 a protective serum antibody titer of >/=0.01 IU/mL.

37 al of intercepts: copies/ml, -0.52 to -1.01; IU/ml, 0.07 to -0.36).

38 mmunoassay had a limit of detection of 0.011 IU/mL and a limit of quantification of 0.012 IU/mL.

39 IU/mL and a limit of quantification of 0.012 IU/mL.

40 50 IU/mL by the end of treatment (all <0.05 IU/mL); five maintained this level of suppression at the

41 the protective human antibody limit of 0.06 IU/mL.

42 IU/mL in patients with CSU and 0.27 +/- 0.08 IU/mL in control subjects, with 80% of patients with CSU

43 dard, 1.11 IU/copy; secondary standard, 1.09 IU/copy).

44 Patients with a trough level of 0.1 IU/mL or lower received enoxaparin sodium increased by 1

45 (95% confidence interval [CI], 19.2 to 44.1 IU/ml).

46 /L) and alanine aminotransferase (ALT, >56.1 IU/L), to the relationships of HBV and HCV infection to

47 The serum hCG level was 8.1 IU/L, and there were residual lesions in the liver and l

48 atients who had HBsAg levels of less than <1 IU/mL before the introduction of pegylated interferon al

49 Oxytocin (1 IU in 20 mul of ACSF) or placebo was injected into the b

50 aminotransaminase 27 +/- 13 versus 27 +/- 10 IU/L (P = 0.81), gamma-glutamyl transferase 54 +/- 138 v

51 19) whose HBsAg levels ever dropped below 10 IU/mL, only one and three patients subsequently develope

52 nce-daily insulin glargine (starting dose 10 IU per day, then titrated weekly to a pre-breakfast self

53 vation, defined as detectable HBV DNA (>/=10 IU/mL).

54 Nine patients had suppressed HBV DNA (<10 IU/mL]) at the end of treatment, which was maintained by

55 ) the definition of immunity to RV as the 10-IU/ml usual cutoff as well as the use of quantitative re

56 sin (DDAVP), peak VWF:Ag levels exceeded 100 IU/dL in 88% of patients and was sustained >100 IU/dL af

57 dL in 88% of patients and was sustained >100 IU/dL after 4 hours in 72% of subjects.

58 ce per week with adjustments to dose (</=100 IU/kg per infusion) or dosing frequency (up to two times

59 effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients

60 splant recipients with HBV DNA less than 100 IU/mL pre-LT.

61 th pretransplant HBV DNA undetectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and d

62 to mothers assigned to cholecalciferol 1000 IU/day did not significantly differ from that of infants

63 mentation of women with cholecalciferol 1000 IU/day during pregnancy did not lead to increased offspr

64 locks of ten, to either cholecalciferol 1000 IU/day or matched placebo, taken orally, from 14 weeks'

65 n to placebo and 565 to cholecalciferol 1000 IU/day.

66 y oral supplementation with vitamin D3 (1000 IU) or calcium carbonate (1200 mg elemental calcium) or

67 ed one dosage of daily oral vitamin D3 (1000 IU), or a group who received 2 dosages of daily oral vit

68 CMV disease or asymptomatic viremia (>/=1000 IU/mL) requiring treatment were identified by chart revi

69 HBV reactivation was defined as a >1000 IU/mL increase in HBV DNA or HBsAg detection in a person

70 ntravenous to subcutaneous HBIg (500 or 1000 IU weekly or fortnightly, adjusted according to serum an

71 aged at least 18 years, with more than 1000 IU/mL HCV RNA, and a laboratory result at screening indi

72 serum HBsAg concentrations of more than 1000 IU/mL, and a history of HDV infection for 6 months or mo

73 ompared with placebo, but did show that 1000 IU of cholecalciferol daily is sufficient to ensure that

74 linearity at lower concentrations (5 to 1000 IU/ml) were assessed for cobas 6800/8800 HCV and cobas 4

75 g pregnancy of 2000 IU/d (compared with 1000 IU/d and with a placebo) results in a higher VDA of brea

76 bo group, 51 IU/L (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) in the 2000-IU grou

77 wed a month later by monthly doses of 100000 IU, or placebo for a median of 3.3 years (range, 2.5-4.2

78 was 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respectively.

79 078, 95% CI = -0.052, 0.254) and 0.497 x 106 IU/m2 (SE = 0.092, 95% CI = 0.316, 0.678), respectively.

80 and 20% increases in Tregs were 0.101 x 106 IU/m2 (standard error [SE] = 0.078, 95% CI = -0.052, 0.2

81 he lowest doses (0.040 x 106 and 0.045 x 106 IU/m2) administered.

82 ed single doses from 0.04 x 106 to 1.5 x 106 IU/m2, in order to model the dose-response curve.

83 d conversion factors (primary standard, 1.11 IU/copy; secondary standard, 1.09 IU/copy).

84 QR) antirachitic activity of 77 IU/d (52-110 IU/d).

85 , human chorionic gonadotropin (hCG) 151,111 IU/L, and lactate dehydrogenase 588 U/L.

86 erfusate alanine transaminase level was 1152 IU/L and urea concentration was 9.4 mmol/L.

87 < .01), greater total IgE levels (197 vs 120 IU/mL, P < .01), and a greater proportion with uncontrol

88 , the mean (95% CI) VDA was 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L

89 with the lowest intake [quintile median: 148 IU/d; HR: 0.83 (95% CI: 0.72, 0.95); P-trend = 0.03].

90 logical response [SVR]12 (SVR of HCV RNA <15 IU/mL 12 weeks after the end of therapy).

91 the percentage of patients with HCV RNA <15 IU/mL 12 weeks after therapy (SVR12).

92 sustained virological response (HCV RNA <15 IU/mL) 12 weeks after the last dose of study drug (SVR12

93 al response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment week 12 (SVR12) in patients wit

94 ponse at post-treatment week 12 (HCV RNA <15 IU/mL).

95 HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12).

96 d unquantifiable or target not detected [<15 IU/mL]).

97 onth followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group).

98 IU/L) in the placebo group, 51 IU/L (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) i

99 enter trial that investigated tinzaparin 175 IU/kg once daily or dose-adjusted warfarin for 6 months

100 2 to -11) and serum ACE activity (Delta, -18 IU/L; 95% CI, -23 to -12) versus placebo (between-group

101 vated alanine aminotransferase levels (>/=19 IU/L for women and >/=30 IU/L for men), incarcerated per

102 an those who maintained values less than 0.2 IU/ml over 2 years (P = 0.0003).

103 e findings suggest that values less than 0.2 IU/ml were true negatives.

104 ividuals with IFN-gamma values less than 0.2 IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml, and greater than

105 exposure had IFN-gamma values less than 0.2 IU/ml.

106 (95% detection rate) of this assay was 25.2 IU/ml (95% confidence interval [CI], 19.2 to 44.1 IU/ml)

107 ected and observed results) with LODs of 8.2 IU/ml and 11.7 IU/ml, respectively, for GT 1.

108 unger than 12 years with haemophilia B (</=2 IU/dL [</=2%] endogenous coagulation factor IX [FIX] act

109 viduals with alanine aminotransferase <22/20 IU/mL.

110 udy serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); presence of 15% or m

111 or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month fo

112 erquartile range) dose of 2000 IU (1500-2000 IU).

113 ved 2 dosages of daily oral vitamin D3 (2000 IU).

114 apses were defined as viral DNA levels >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL

115 a median (interquartile range) dose of 2000 IU (1500-2000 IU).

116 d 1 to 5 years, daily administration of 2000 IU compared with 400 IU of vitamin D supplementation did

117 n D supplementation during pregnancy of 2000 IU/d (compared with 1000 IU/d and with a placebo) result

118 For M65, a cutoff of 2000 IU/L had a positive predictive value of 91%, whereas a c

119 participants were randomized to receive 2000 IU/d of vitamin D oral supplementation (high-dose group)

120 A total of 204 T2DM subjects received 2000 IU vitamin D3 daily for 12 months.

121 p (vitamin D3 + calcium group) received 2000 IU/d of vitamin D3 and 1500 mg/d of calcium; the placebo

122 roup, and 74 IU/L (25, 221 IU/L) in the 2000-IU group; and at age 2 mo, the mean (95% CI) VDA was 45

123 Oral vitamin D3 in an initial dose of 200000 IU, followed a month later by monthly doses of 100000 IU

124 aminotransaminase 33 +/- 22 versus 37 +/- 21 IU/L (P = 0.10), aspartate aminotransaminase 27 +/- 13 v

125 95% CI) VDA at age 2 wk was 52 IU/L (12, 217 IU/L) in the placebo group, 51 IU/L (17, 151 IU/L) in th

126 ; 1.60] and total daily insulin dose by 6.22 IU [8.04; 4.40].

127 ) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) in the 2000-IU group; and at age 2 mo, the mean (9

128 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respectively.

129 levels of IgE-anti-IL-24 were 0.52 +/- 0.24 IU/mL in patients with CSU and 0.27 +/- 0.08 IU/mL in co

130 eutic window determined in vitro (0.015-0.24 IU/ml), even at the lowest doses (0.040 x 106 and 0.045

131 sessed the effect of intranasal oxytocin (24 IU) administered to 29 healthy, fasted male subjects on

132 drinkers showed that intranasal oxytocin (24 IU) decreased neural cue-reactivity in brain networks si

133 udy with single-dose intranasal oxytocin (24 IU) in ten overweight or obese, otherwise healthy men.

134 volunteers received intranasal oxytocin (24 IU) or placebo in a double-blind, randomized crossover s

135 tained virologic response (serum HCV RNA <25 IU/mL) 12 weeks after treatment ended (SVR12).

136 sustained virological response (HCV RNA <25 IU/mL) at post-treatment week 12 (SVR12) in the intentio

137 quivalent to serum HCV RNA levels of 150-250 IU/mL; using nondenaturation of serum samples, our HCV-A

138 see no increased risk for thrombosis at 250 IU/kg FIX at 6 hours postinfusion.

139 A cytomegalovirus viral load of 250 IU/mL or greater was associated with increased risk of e

140 ts have lower cut points for IgE levels (268 IU), fraction of exhaled nitric oxide values (14.5 ppb),

141 proxil fumarate who had HBV DNA less than 29 IU/mL (adjusted difference -3.6% [95% CI -9.8 to 2.6]; p

142 ion of patients who had HBV DNA less than 29 IU/mL at week 48 in those who received at least one dose

143 nofovir alafenamide had HBV DNA less than 29 IU/mL at week 48 versus 130 (93%) of 140 patients receiv

144 nofovir alafenamide had HBV DNA less than 29 IU/mL at week 48, which was non-inferior to the 195 (67%

145 g at a protective titer of approximately 290 IU/L.

146 P=0.02), as was factor use (mean dose, 2908 IU per kilogram [range, 0 to 8090] before vector adminis

147 istic curve of 0.86) for HEV exposure at 0.3 IU/mL.

148 erum hCG levels after chemotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks.

149 8090] before vector administration vs. 49.3 IU per kilogram [range, 0 to 376] after administration;

150 Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or

151 samples with viral loads of 10(4) and 10(3) IU/ml respectively.

152 as subjects with type 1 VWD and VWF:Ag >/=30 IU/dL had an intermediate frequency of variants (44%).

153 erase levels (>/=19 IU/L for women and >/=30 IU/L for men), incarcerated persons, pregnant women, and

154 re most frequent in subjects with VWF:Ag <30 IU/dL (82%), whereas subjects with type 1 VWD and VWF:Ag

155 man penis would be exposed to at least 2,300 IU of HCV for the duration of anal intercourse.

156 MATERIALS AND Ten patients (IgE>300 IU/mL and <700 IU/mL) with a significant response to all

157 lation with HCV RNA levels greater than 3000 IU/mL and have the potential to replace NAT in settings

158 emotherapy were 12.3 IU/L at 2 weeks and 325 IU/L at 4 weeks.

159 rol subjects having levels greater than 0.33 IU/mL (P < .0001).

160 N-gamma values less than 0.2 IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml, and greater than 0.7 IU/ml, tuber

161 At the cutoff value of 3 mm for SPT and 0.35 IU/mL for sIgE, SPT has a higher specificity for asthma

162 ty (P<.0001) than sIgE (cutoff value at 0.35 IU/mL) and the specificity was not different between bot

163 0 times the recommended test threshold (0.35 IU/mL).

164 ntitative QFT result (interferon-gamma <0.35 IU/mL, 0.35-4.00 IU/mL, and >4.00 IU/mL) at the intermed

165 amyl transferase 54 +/- 138 versus 49 +/- 35 IU/L (P = 0.72), Fatty Liver Index 58.9 +/- 24.6 versus

166 weekly at an equivalent dose of 600 or 3750 IU/d.

167 ean endogenous FIX activity increased to 4.4 IU/dL.

168 terquartile range, 10.0-20.7 IU/L versus 8.4 IU/L; interquartile range, 7.6-9.0 IU/L; P<0.01), these

169 randomized to intranasal oxytocin (8 days/40 IU twice daily) or placebo (8 days/10 puffs twice daily)

170 ing two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice

171 e follicle-stimulating hormone value of > 40 IU/L after 2 years of follow up.

172 ntramuscular tetracosactide depot 0.5 mg (40 IU) on alternate days with or without vigabatrin 100 mg/

173 to 78 min after onset of treatment onset (40 IU of IN-OT or placebo).

174 reditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI

175 acebo group to 1.13 uses per month in the 40-IU group and from 3.89 uses in the placebo group to 0.32

176 min D plus a prenatal vitamin containing 400 IU vitamin D, and 436 women were randomized to receive a

177 acebo plus a prenatal vitamin containing 400 IU vitamin D.

178 supplemented with 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were analyzed for immune cel

179 ticipants who were randomized to receive 400 IU/d (standard-dose group) for a minimum of 4 months bet

180 of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10-18 weeks), on

181 administration of 2000 IU compared with 400 IU of vitamin D supplementation did not reduce overall w

182 pants received 1000 mg elemental Ca with 400 IU vitamin D3/d or placebo (median follow-up: 6.5 y).

183 ith 4400 IU/d of vitamin D compared with 400 IU/d significantly increased vitamin D levels in the wom

184 401 (30.4%, 95% CI, 25.7%-73.1%) in the 400-IU group (hazard ratio, 0.8; 95% CI, 0.6-1.0; P = .051).

185 100,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or a matching placebo for 16 wk.

186 women were randomized to receive daily 4000 IU vitamin D plus a prenatal vitamin containing 400 IU v

187 upplementation at 1 of 2 doses (2000 or 4000 IU) or a matching placebo for 16 wk.

188 lementation in pregnancy (400, 2000, or 4000 IU/d).Treatment had no significant effect on changes in

189 1 esterase inhibitor (50 IU/kg; maximum 4200 IU) twice weekly, recombinant human C1 esterase inhibito

190 (95% CI) VDA was 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respect

191 Supplementation of mothers with 4400 IU of vitamin D3 resulted in an enhanced broad-spectrum

192 nates born to mothers supplemented with 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were an

193 child with asthma, supplementation with 4400 IU/d of vitamin D compared with 400 IU/d significantly i

194 munity of maternal supplementation with 4400 IU/d vitamin D3 during the second and third trimesters o

195 405 (24.3%; 95% CI, 18.7%-28.5%) in the 4400-IU group vs 120 of 401 (30.4%, 95% CI, 25.7%-73.1%) in t

196 nd at age 2 mo, the mean (95% CI) VDA was 45 IU/L (16, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L

197 significantly less IFN-gamma (1.85 vs. 3.48 IU/ml; P = 0.02) and IL-2 (46.17 vs. 84.03 pg/ml; P = 0.

198 ed virus neutralising antibody titres of 0.5 IU/mL or more across dose levels and schedules in 32 (71

199 dermal dose of CV7201 achieved titres of 0.5 IU/mL or more.

200 O-specified protective antibody titre of 0.5 IU/mL.

201 L) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-15

202 cutoff value of 3 and 5 mm for SPT, and 3.5 IU/mL for sIgE.

203 ry tests revealed a rheumatoid factor of 8.5 IU/mL (normal range, 0-13.9 IU/mL), an erythrocyte sedim

204 e factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transf

205 ow von Willebrand factor (VWF) levels (30-50 IU/dL).

206 articipants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after re

207 recombinant human C1 esterase inhibitor (50 IU/kg; maximum 4200 IU) twice weekly, recombinant human

208 Six patients had HBsAg levels less than 50 IU/mL by the end of treatment (all <0.05 IU/mL); five ma

209 on of patients with serum HBsAg less than 50 IU/mL, the proportion of patients with suppressed HBV DN

210 e with plasma VWF levels within the 30 to 50 IU/dL range.

211 ntratracheal lipopolysaccharide model, 1,500 IU of intraperitoneal cholecalciferol treatment 6 hours

212 hropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); presence of 15% or more ring sider

213 entration (<200 IU/L, 200-500 IU/L, and >500 IU/L); presence of 15% or more ring sideroblasts; and pr

214 id virological response (plasma HCV RNA <500 IU/mL by day 2, measured by COBAS TaqMan HCV test, versi

215 els identified a cutoff CMV DNA level of 500 IU/mL to differentiate between CMV pneumonia and pulmona

216 s observed while for others it was up to 500 IU/mL.

217 tectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and daily for 5 days together with

218 IU/L (12, 217 IU/L) in the placebo group, 51 IU/L (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (2

219 ) consumed a single amount of vitamin D (511 IU/d from diet and a cholecalciferol supplement) for 10

220 The mean (95% CI) VDA at age 2 wk was 52 IU/L (12, 217 IU/L) in the placebo group, 51 IU/L (17, 1

221 e of dietary vitamin D (quintile median: 528 IU/d) had a significant 17% lower risk of early menopaus

222 6, 124 IU/L), 43 IU/L (18, 103 IU/L), and 58 IU/L (15, 224 IU/L), respectively.

223 average prophylactic dose of rFIXFc was 58.6 IU/kg (IQR 52.3-64.8) per week.

224 ractory cGVHD received daily IL-2 (1 x 10(6) IU/m(2)) for 12 weeks.

225 edian baseline HCV viral load of 1.3 x 10(6) IU/mL and Metavir fibrosis stage 1 and genotype-1a.

226 ong men with an HCV RNA load of >/=2 x 10(6) IU/mL, compared with findings among men without chronic

227 re initially given rFIXFc prophylaxis (50-60 IU/kg) once per week with adjustments to dose (</=100 IU

228 participants received intranasal insulin (60 IU) or placebo (8.7% sodium chloride).

229 e administered either intranasal insulin (60 IU) or placebo, following which they participated in the

230 6-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly fo

231 -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P<0

232 acebo group to 0.32 uses per month in the 60-IU group.

233 redonation alanine transaminase level was 63 IU/L, and the period from withdrawal of life-supporting

234 ictive value of 91%, whereas a cutoff of 641 IU/L had a negative predictive value of 88%.

235 alues from less than 0.2 to greater than 0.7 IU/ml had 10-fold higher tuberculosis incidence rates th

236 ion (an increase from IFN-gamma <0.2 to >0.7 IU/ml) would allow more definitive detection of recent M

237 e value within the uncertainty zone (0.2-0.7 IU/ml), were partly explained by technical assay variabi

238 ess than 0.2 IU/ml, 0.2-0.34 IU/ml, 0.35-0.7 IU/ml, and greater than 0.7 IU/ml, tuberculin skin test

239 ulosis had IFN-gamma values greater than 0.7 IU/ml, suggesting that these values are consistent with

240 IU/ml, 0.35-0.7 IU/ml, and greater than 0.7 IU/ml, tuberculin skin test positivity results were 15%,

241 (88.6%) fell within the range of 0.2 to 0.7 IU/ml.

242 ved results) with LODs of 8.2 IU/ml and 11.7 IU/ml, respectively, for GT 1.

243 s (13.8 IU/L; interquartile range, 10.0-20.7 IU/L versus 8.4 IU/L; interquartile range, 7.6-9.0 IU/L;

244 e defined atopy based on specific IgE > 0.70 IU/mL to at least 1 of 10 allergens measured in blood.

245 ALS AND Ten patients (IgE>300 IU/mL and <700 IU/mL) with a significant response to allergen challenge

246 n ALGS after PEBD (182 +/- 70 vs. 260 +/- 73 IU/L, preoperatively vs. 24 months; P = 0.03), but not i

247 (17, 151 IU/L) in the 1000-IU group, and 74 IU/L (25, 221 IU/L) in the 2000-IU group; and at age 2 m

248 tionally, an extended dynamic range of 0-750 IU/mL was observed while for others it was up to 500 IU/

249 o a median (IQR) antirachitic activity of 77 IU/d (52-110 IU/d).

250 higher than those of healthy controls (13.8 IU/L; interquartile range, 10.0-20.7 IU/L versus 8.4 IU/

251 ) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032).

252 We administered d5 OT (80 IU) to six nonhuman primates via IN and IV routes as wel

253 id factor of 8.5 IU/mL (normal range, 0-13.9 IU/mL), an erythrocyte sedimentation rate of 2 mm/hr (no

254 of liver damage, high aspartate (AST, >49.9 IU/L) and alanine aminotransferase (ALT, >56.1 IU/L), to

255 e cohort, mean FIX activity increased to 6.9 IU/dL.

256 (NIT) were higher in independent facilities (IUs) as compared to contracted facilities (CFs).

257 ith a laboratory-developed BKV NAAT assay in IU/ml versus copies/ml using Passing-Bablok regression r

258 The U-M bond in IU(IV)(mu-OAr(P)-1kappa(1)O,2kappa(1)P)3M(0), M = Ni (3-

259 CFT value for treatment of macular edema in IU, in the presence of other relevant morphological feat

260 of CFT for systemic treatment initiation in IU was statistically identified and its sensitivity and

261 uction of bias when results were reported in IU/ml (IU/ml, -0.10 log10; copies/ml, -0.70 log10).

262 cells or extracts, adding Usp14 inhibitors (IU-1 or ubiquitin aldehyde) enhanced Usp14 and Ube3c bin

263 he conversion of results from copies/mL into IU/mL for HDVL standardization and interlaboratory compa

264 s, and several others underestimated (>3 log IU/mL) HDVL of African genotype strains (1 and 5-8).

265 for patients with non-CMV pneumonia, 0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with IPS, an

266 2.6-6.0 log10 IU/mL) than controls (0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with non-CMV

267 mL; interquartile range [IQR], 2.6-6.0 log10 IU/mL) than controls (0 log10 IU/mL [IQR, 0-1.6 log10 IU

268 defined as an increase in HCV-RNA >/=1 log10 IU/mL over baseline and hepatitis flare as an increase i

269 and higher HBV DNA levels (median, 3.2 log10 IU/mL vs. 2.8 log10 IU/mL; P = 0.03) compared with East

270 owed a standard deviation (SD) of 0.22 log10 IU/ml or lower for each level tested.

271 patients (mean decline at week 2, 3.27 log10 IU/mL).

272 ar at low HCV RNA concentrations (<0.3 log10 IU/ml difference between expected and observed results)

273 2 (IQR 3.23-5.00) and 5.07 (4.19-5.35) log10 IU/mL in patients dosed with 2 mg/kg RG-101 or 4 mg/kg R

274 tions (median, 0.94 [range, 0.69-1.35] log10 IU/mL) (P < .001); 58.9% of all clinical sample results

275 IU/mL (interquartile range, 4.47-7.37 log10 IU/mL), respectively.

276 At baseline, median HCV RNA was 5.4 log10 IU/mL (interquartile range 4.4-6.8) and median estimated

277 6 standard deviation) of 0.03 +/- 0.44 log10 IU/ml.

278 dding was associated with blood VL > 5 log10 IU/mL (p = .01), and 85% with blood VL > 5 log10 IU/mL h

279 L (p = .01), and 85% with blood VL > 5 log10 IU/mL had rectal shedding.

280 IS dilution results fell within +/-0.5 log10 IU/mL of the mean viral load of each sample.

281 women with an HBsAg level above 4-4.5 log10 IU/mL to interrupt mother-to-infant transmission.

282 he rectal fluid ranged from 2.6 to 5.5 log10 IU/mL.

283 IPS, and 1.63 log10 IU/mL [IQR, 0-2.5 log10 IU/mL] for patients who were asymptomatic; P < .001 for

284 V pneumonia, 0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with IPS, and 1.63 log10 IU/mL [IQR,

285 an controls (0 log10 IU/mL [IQR, 0-1.6 log10 IU/mL] for patients with non-CMV pneumonia, 0 log10 IU/m

286 IU/mL] for patients with IPS, and 1.63 log10 IU/mL [IQR, 0-2.5 log10 IU/mL] for patients who were asy

287 maternal viral load above 6, 7, and 8 log10 IU/mL with an area under the receiver operating characte

288 evels (median, 3.2 log10 IU/mL vs. 2.8 log10 IU/mL; P = 0.03) compared with East African FBAAs.

289 mples (median, 1.50 [range, 1.22-2.82] log10 IU/mL) than for IS dilutions (median, 0.94 [range, 0.69-

290 uartile range, 1938-3078 U/L) and 5.88 log10 IU/mL (interquartile range, 4.47-7.37 log10 IU/mL), resp

291 nia had higher median viral loads (3.9 log10 IU/mL; interquartile range [IQR], 2.6-6.0 log10 IU/mL) t

292 nt samples was shown from 1.34 to 6.94 log10 IU/ml.

293 nfection (adjusted odds ratio for each log10 IU/mL increase, 15.02; 95% confidence interval [CI], 3.8

294 iral Load assay results (quantified in log10 IU per milliliter) were within 1 standard deviation of t

295 The concordances using the 6 million IU/ml cutoff were high among all four assays (90 to 94%)

296 d a mean baseline viral load of 7.79 million IU/mL, were treated.

297 of bias when results were reported in IU/ml (IU/ml, -0.10 log10; copies/ml, -0.70 log10).

298 ples contained more than 10 000 copies/mL or IU/mL, respectively, as determined by quantitative PCR.

299 rated the results to the international unit (IU) using the Exact Diagnostics BKV verification panel,

300 61 consecutive patients with IU presenting over a 6-year period were prospectively re

301 Two subgroups of patients with IU were identified on the basis of the need or not for s